Indian Industry Gets HCQ, Paracetamol Exports Rolling
Supplies Sent To US, UK And Others
Indian manufacturers hope increased production of hydroxychloroquine and paracetamol, along with emergence of reliable COVID-19 therapies, will lead to export restrictions on these two medicines being removed soon. Meanwhile, they are fulfilling orders routed through the government.
You may also be interested in...
Asia Deal Watch: Aditum Bio Launches Vitalli To Develop Daewoong Immunology Candidate
In addition, deals involving Lupin/Medisol, Junshi/Dr. Reddy's, Zai Lab/MediLink, Kyowa Kirin/ADVANZ, Ipca/Unichem, Jiangsu Aidea/Kainos.
Scorching COVID-19 Era Returns From India Biotech, Healthcare Funds Outpace The Globe
Early COVID-19 therapies including Gilead’s remdesivir, China-plus procurement policies, vaccine partnerships and a dovish stance by the central bank led to returns on India biotech and healthcare funds outperforming global returns. Meanwhile, funding for e-pharmacies and online consulting firms gathered pace.
Is Dexamethasone The Next Hydroxychloroquine For India?
While the jury is still out on dexamethasone being the new hero in the fight against COVID-19 after the hype around hydroxychloroquine has died down, Indian pharma is watching developments closely. Gains of companies like Zydus Cadila, Wockhardt, Cadila and Cipla in the domestic market will be constrained by price caps while any increase in exports will depend on emergency use authorizations.